• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对比增强磁共振成像上的大血管网络改善新诊断胶质母细胞瘤的生存预测

Macrovascular Networks on Contrast-Enhanced Magnetic Resonance Imaging Improves Survival Prediction in Newly Diagnosed Glioblastoma.

作者信息

Puig Josep, Biarnés Carles, Daunis-I-Estadella Pepus, Blasco Gerard, Gimeno Alfredo, Essig Marco, Balaña Carme, Alberich-Bayarri Angel, Jimenez-Pastor Ana, Camacho Eduardo, Thio-Henestrosa Santiago, Capellades Jaume, Sanchez-Gonzalez Javier, Navas-Martí Marian, Domenech-Ximenos Blanca, Del Barco Sonia, Puigdemont Montserrat, Leiva-Salinas Carlos, Wintermark Max, Nael Kambiz, Jain Rajan, Pedraza Salvador

机构信息

Department of Radiology, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.

Research Unit of Diagnostic Imaging Institute (IDI), Department of Radiology (Girona Biomedical Research Institute) IDIBGI, Hospital Universitari Dr Josep Trueta, 17007 Girona, Spain.

出版信息

Cancers (Basel). 2019 Jan 14;11(1):84. doi: 10.3390/cancers11010084.

DOI:10.3390/cancers11010084
PMID:30646519
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6356693/
Abstract

A higher degree of angiogenesis is associated with shortened survival in glioblastoma. Feasible morphometric parameters for analyzing vascular networks in brain tumors in clinical practice are lacking. We investigated whether the macrovascular network classified by the number of vessel-like structures (nVS) visible on three-dimensional T1-weighted contrast⁻enhanced (3D-T1CE) magnetic resonance imaging (MRI) could improve survival prediction models for newly diagnosed glioblastoma based on clinical and other imaging features. Ninety-seven consecutive patients (62 men; mean age, 58 ± 15 years) with histologically proven glioblastoma underwent 1.5T-MRI, including anatomical, diffusion-weighted, dynamic susceptibility contrast perfusion, and 3D-T1CE sequences after 0.1 mmol/kg gadobutrol. We assessed nVS related to the tumor on 1-mm isovoxel 3D-T1CE images, and relative cerebral blood volume, relative cerebral flow volume (rCBF), delay mean time, and apparent diffusion coefficient in volumes of interest for contrast-enhancing lesion (CEL), non-CEL, and contralateral normal-appearing white matter. We also assessed Visually Accessible Rembrandt Images scoring system features. We used ROC curves to determine the cutoff for nVS and univariate and multivariate cox proportional hazards regression for overall survival. Prognostic factors were evaluated by Kaplan-Meier survival and ROC analyses. Lesions with nVS > 5 were classified as having highly developed macrovascular network; 58 (60.4%) tumors had highly developed macrovascular network. Patients with highly developed macrovascular network were older, had higher volume, increased rCBF, and poor survival; nVS correlated negatively with survival ( = -0.286; = 0.008). On multivariate analysis, standard treatment, age at diagnosis, and macrovascular network best predicted survival at 1 year (AUC 0.901, 83.3% sensitivity, 93.3% specificity, 96.2% PPV, 73.7% NPV). Contrast-enhanced MRI macrovascular network improves survival prediction in newly diagnosed glioblastoma.

摘要

胶质母细胞瘤中较高程度的血管生成与生存期缩短相关。临床实践中缺乏用于分析脑肿瘤血管网络的可行形态学参数。我们研究了通过三维T1加权对比增强(3D-T1CE)磁共振成像(MRI)上可见的血管样结构数量(nVS)分类的大血管网络是否能基于临床和其他影像学特征改善新诊断胶质母细胞瘤的生存预测模型。97例经组织学证实为胶质母细胞瘤的连续患者(62例男性;平均年龄58±15岁)接受了1.5T-MRI检查,包括解剖、扩散加权、动态磁敏感对比灌注以及在静脉注射0.1 mmol/kg钆布醇后的3D-T1CE序列。我们在1毫米等体素3D-T1CE图像上评估与肿瘤相关的nVS,以及对比增强病变(CEL)、非CEL和对侧正常白质感兴趣区域的相对脑血容量、相对脑血流量(rCBF)、平均通过时间和表观扩散系数。我们还评估了视觉可及的伦勃朗图像评分系统特征。我们使用ROC曲线确定nVS的临界值,并对总生存期进行单因素和多因素Cox比例风险回归分析。通过Kaplan-Meier生存分析和ROC分析评估预后因素。nVS>5的病变被分类为具有高度发达的大血管网络;58例(60.4%)肿瘤具有高度发达的大血管网络。具有高度发达大血管网络的患者年龄较大、体积较大、rCBF增加且生存期较差;nVS与生存期呈负相关(r=-0.286;P=0.008)。多因素分析显示,标准治疗、诊断时年龄和大血管网络最能预测1年生存期(AUC 0.901,灵敏度83.3%,特异度93.3%,阳性预测值96.2%,阴性预测值73.7%)。对比增强MRI大血管网络可改善新诊断胶质母细胞瘤的生存预测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec32/6356693/86c254510e52/cancers-11-00084-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec32/6356693/8df10827c83d/cancers-11-00084-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec32/6356693/b81273cb24be/cancers-11-00084-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec32/6356693/86c254510e52/cancers-11-00084-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec32/6356693/8df10827c83d/cancers-11-00084-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec32/6356693/b81273cb24be/cancers-11-00084-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec32/6356693/86c254510e52/cancers-11-00084-g003.jpg

相似文献

1
Macrovascular Networks on Contrast-Enhanced Magnetic Resonance Imaging Improves Survival Prediction in Newly Diagnosed Glioblastoma.对比增强磁共振成像上的大血管网络改善新诊断胶质母细胞瘤的生存预测
Cancers (Basel). 2019 Jan 14;11(1):84. doi: 10.3390/cancers11010084.
2
High-resolution blood-pool-contrast-enhanced MR angiography in glioblastoma: tumor-associated neovascularization as a biomarker for patient survival. A preliminary study.胶质母细胞瘤的高分辨率血池对比增强磁共振血管造影:肿瘤相关新生血管作为患者生存的生物标志物。一项初步研究。
Neuroradiology. 2016 Jan;58(1):17-26. doi: 10.1007/s00234-015-1599-0. Epub 2015 Oct 5.
3
Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.在预测新诊断胶质母细胞瘤的生存率方面,临床参数比基于扩散和灌注的MRI参数更为重要。
Neuro Oncol. 2016 Dec;18(12):1673-1679. doi: 10.1093/neuonc/now122. Epub 2016 Jun 13.
4
Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: Comparison of intraindividually matched T1 - and T2 (*) -based bolus techniques.新诊断胶质母细胞瘤患者的总生存期与对比增强灌注MRI的相关性:基于T1和T2(*)的团注技术个体内匹配比较
J Magn Reson Imaging. 2015 Jul;42(1):87-96. doi: 10.1002/jmri.24756. Epub 2014 Sep 22.
5
Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma: a novel diagnostic and specific prognostic indicator.弥散加权成像上表现为非增强性瘤周高信号病变的胶质母细胞瘤:一种新的诊断及特异性预后指标。
J Neurosurg. 2018 Mar;128(3):667-678. doi: 10.3171/2016.10.JNS161694. Epub 2017 Mar 31.
6
Radiomic Analysis Reveals Prognostic Information in T1-Weighted Baseline Magnetic Resonance Imaging in Patients With Glioblastoma.放射组学分析揭示胶质母细胞瘤患者T1加权基线磁共振成像中的预后信息。
Invest Radiol. 2017 Jun;52(6):360-366. doi: 10.1097/RLI.0000000000000349.
7
T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor vIII Status.T1加权动态对比增强磁共振成像作为表皮生长因子受体vIII状态的无创生物标志物
AJNR Am J Neuroradiol. 2015 Dec;36(12):2256-61. doi: 10.3174/ajnr.A4484. Epub 2015 Sep 3.
8
Evaluation of tumor shape features for overall survival prognosis in glioblastoma multiforme patients.评估胶质母细胞瘤患者的肿瘤形状特征对总生存期预后的影响。
Surg Oncol. 2019 Jun;29:178-183. doi: 10.1016/j.suronc.2019.05.005. Epub 2019 May 17.
9
Texture Analysis of the Apparent Diffusion Coefficient Focused on Contrast-Enhancing Lesions in Predicting Survival for Bevacizumab-Treated Patients with Recurrent Glioblastoma.聚焦于对比增强病变的表观扩散系数纹理分析在预测贝伐单抗治疗的复发性胶质母细胞瘤患者生存率中的应用
Cancers (Basel). 2023 Jun 1;15(11):3026. doi: 10.3390/cancers15113026.
10
Intravoxel Incoherent Motion Metrics as Potential Biomarkers for Survival in Glioblastoma.体素内不相干运动指标作为胶质母细胞瘤生存的潜在生物标志物
PLoS One. 2016 Jul 7;11(7):e0158887. doi: 10.1371/journal.pone.0158887. eCollection 2016.

引用本文的文献

1
[Current Applications and Future Perspectives of Brain Tumor Imaging].[脑肿瘤成像的当前应用及未来展望]
Taehan Yongsang Uihakhoe Chi. 2020 May;81(3):467-487. doi: 10.3348/jksr.2020.81.3.467. Epub 2020 May 29.
2
Evaluating angioarchitectural characteristics of glial and metastatic brain tumors with conventional magnetic resonance imaging.评估胶质和转移性脑肿瘤的血管构筑特征的常规磁共振成像。
J Clin Neurosci. 2020 Jun;76:46-52. doi: 10.1016/j.jocn.2020.04.051. Epub 2020 Apr 17.
3
Glioblastoma: State of the Art and Future Perspectives.

本文引用的文献

1
State of the Art Treatment and Surveillance Imaging of Glioblastomas.胶质母细胞瘤的最新治疗与监测成像
Semin Roentgenol. 2018 Jan;53(1):23-36. doi: 10.1053/j.ro.2017.11.003. Epub 2017 Nov 20.
2
Lomustine and Bevacizumab in Progressive Glioblastoma.洛莫司汀和贝伐珠单抗治疗进展性胶质母细胞瘤。
N Engl J Med. 2017 Nov 16;377(20):1954-1963. doi: 10.1056/NEJMoa1707358.
3
Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges.对比增强灌注 MRI 技术在脑胶质瘤中的临床应用:最新进展与当前挑战。
胶质母细胞瘤:现状与未来展望。
Cancers (Basel). 2019 Jul 31;11(8):1091. doi: 10.3390/cancers11081091.
Contrast Media Mol Imaging. 2017 Mar 20;2017:7064120. doi: 10.1155/2017/7064120. eCollection 2017.
4
Comparison between perfusion computed tomography and dynamic contrast-enhanced magnetic resonance imaging in assessing glioblastoma microvasculature.灌注计算机断层扫描与动态对比增强磁共振成像在评估胶质母细胞瘤微血管系统中的比较。
Eur J Radiol. 2017 Feb;87:120-124. doi: 10.1016/j.ejrad.2016.12.016. Epub 2016 Dec 19.
5
Perfusion Imaging in Neuro-Oncology: Basic Techniques and Clinical Applications.神经肿瘤学中的灌注成像:基本技术与临床应用
Magn Reson Imaging Clin N Am. 2016 Nov;24(4):765-779. doi: 10.1016/j.mric.2016.07.004.
6
High-resolution blood-pool-contrast-enhanced MR angiography in glioblastoma: tumor-associated neovascularization as a biomarker for patient survival. A preliminary study.胶质母细胞瘤的高分辨率血池对比增强磁共振血管造影:肿瘤相关新生血管作为患者生存的生物标志物。一项初步研究。
Neuroradiology. 2016 Jan;58(1):17-26. doi: 10.1007/s00234-015-1599-0. Epub 2015 Oct 5.
7
Preoperative biomarkers of tumour vascularity are elevated in patients with glioblastoma multiforme.多形性胶质母细胞瘤患者术前肿瘤血管生成的生物标志物升高。
J Clin Neurosci. 2015 Nov;22(11):1802-8. doi: 10.1016/j.jocn.2015.06.013. Epub 2015 Aug 22.
8
Glioma Angiogenesis and Perfusion Imaging: Understanding the Relationship between Tumor Blood Volume and Leakiness with Increasing Glioma Grade.胶质瘤血管生成与灌注成像:了解随着胶质瘤分级增加肿瘤血容量与渗漏之间的关系。
AJNR Am J Neuroradiol. 2015 Nov;36(11):2030-5. doi: 10.3174/ajnr.A4405. Epub 2015 Jul 23.
9
Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients.胶质母细胞瘤患者中使用动态磁敏感对比增强磁共振成像测量脑灌注的可重复性
Transl Oncol. 2015 Jun;8(3):137-46. doi: 10.1016/j.tranon.2015.03.002.
10
Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.相对脑血容量是复发性胶质母细胞瘤中贝伐单抗疗效的一种潜在预测性影像生物标志物。
Neuro Oncol. 2015 Aug;17(8):1139-47. doi: 10.1093/neuonc/nov028. Epub 2015 Mar 9.